Compare OMER & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMER | JANX |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2008 | 2021 |
| Metric | OMER | JANX |
|---|---|---|
| Price | $13.29 | $10.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 18 |
| Target Price | $27.50 | ★ $33.14 |
| AVG Volume (30 Days) | ★ 1.2M | 946.4K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $29,868,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | $174.21 |
| Revenue Next Year | $66.13 | N/A |
| P/E Ratio | $107.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.70 | $10.16 |
| 52 Week High | $21.24 | $35.34 |
| Indicator | OMER | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 25.34 |
| Support Level | $9.45 | N/A |
| Resistance Level | $19.68 | $14.47 |
| Average True Range (ATR) | 0.92 | 1.16 |
| MACD | -0.45 | -0.48 |
| Stochastic Oscillator | 8.90 | 0.33 |
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.